Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the net profit margin high or low?
The net profit margin of 30.74% is 110% above its 5-year average of -296.65%, near the high end of its 5-year range (-1377.12%–43.52%).
140.67% above its 12-month average of -75.58%.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): 43.52%.
NET PROFIT MARGIN
30.74%
NET PROFIT MARGIN AVG TTM
-75.58%
NET PROFIT MARGIN AVG 3Y
-546.98%
NET PROFIT MARGIN AVG 5Y
-296.65%
NET PROFIT MARGIN AVG 10Y
-348.72%
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+140.67%
CURRENT VS 3Y AVG
+105.62%
CURRENT VS 5Y AVG
+110.36%
CURRENT VS 10Y AVG
+108.82%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-0.26%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
+11923.08%
vs the sector median at left
Liquidia Corporation
Market Cap
$2.33B
Net Profit Margin
30.74%
TTM Avg
-75.58%
3Y Avg
-546.98%
5Y Avg
-296.65%
Market Cap
$2.33B
Net Profit Margin
11.45%
TTM Avg
11.51%
3Y Avg
11.51%
5Y Avg
10.20%
Market Cap
$2.35B
Net Profit Margin
-928.44%
TTM Avg
-334.88%
3Y Avg
-330.91%
5Y Avg
-326.71%
Market Cap
$2.36B
Net Profit Margin
32.98%
TTM Avg
37.58%
3Y Avg
5.36%
5Y Avg
-41.08%
Market Cap
$2.30B
Net Profit Margin
-40.18%
TTM Avg
-20.09%
3Y Avg
-20.09%
5Y Avg
-20.09%
Market Cap
$2.29B
Net Profit Margin
18.88%
TTM Avg
19.31%
3Y Avg
25.55%
5Y Avg
15.07%
Market Cap
$2.42B
Net Profit Margin
-945.92%
TTM Avg
-825.68%
3Y Avg
-750.64%
5Y Avg
-1236.10%
Market Cap
$2.40B
Net Profit Margin
-0.74%
TTM Avg
-3.79%
3Y Avg
-13.87%
5Y Avg
-19.28%
Market Cap
$2.41B
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Liquidia Corporation (LQDA) | $2.33B | 30.74% | -75.58% | -546.98% | -296.65% |
| UFP Technologies, Inc. (UFPT)vs › | $2.33B | 11.45% | 11.51% | 11.51% | 10.20% |
| Nurix Therapeutics, Inc. (NRIX)vs › | $2.35B | -928.44% | -334.88% | -330.91% | -326.71% |
| ADMA Biologics, Inc. (ADMA)vs › | $2.36B | 32.98% | 37.58% | 5.36% | -41.08% |
| Alamar Biosciences, Inc. (ALMR)vs › | $2.30B | -40.18% | -20.09% | -20.09% | -20.09% |
| Harmony Biosciences Holdings, Inc. (HRMY)vs › | $2.29B | 18.88% | 19.31% | 25.55% | 15.07% |
| Recursion Pharmaceuticals, Inc. (RXRX)vs › | $2.42B | -945.92% | -825.68% | -750.64% | -1236.10% |
| Clover Health Investments, Corp. (CLOV)vs › | $2.40B | -0.74% | -3.79% | -13.87% | -19.28% |
| Disc Medicine, Inc. (IRON)vs › | $2.41B | 0.00% | 0.00% | 0.00% | 0.00% |
| Supernus Pharmaceuticals, Inc. (SUPN)vs › | $2.45B | -13.23% | 2.90% | 3.78% | 8.12% |
Operating Margin
-32.5%
Net Profit Margin
30.7%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | 43.52% |
| 2026-03-31 | 39.79% |
| 2025-12-31 | 15.82% |
| 2025-09-30 | -6.50% |
| 2025-06-30 | -470.51% |
| 2025-03-31 | -1229.71% |
| 2024-12-31 | -1315.36% |
| 2024-09-30 | -520.57% |
| 2024-06-30 | -763.65% |
| 2024-03-31 | -1377.12% |
| 2023-12-31 | -605.83% |
| 2023-09-30 | -429.31% |
| 2023-06-30 | -491.37% |
| 2023-03-31 | -261.41% |
| 2022-12-31 | -121.88% |
| 2022-09-30 | -287.27% |
| 2022-06-30 | -241.12% |
| 2022-03-31 | -456.56% |
| 2021-12-31 | -359.66% |
| 2021-09-30 | -229.03% |
| 2021-06-30 | -194.08% |
| 2021-03-31 | -297.76% |
| 2020-12-31 | -2174.95% |
| 2020-09-30 | 0.00% |
| 2020-06-30 | 0.00% |
| 2020-03-31 | 0.00% |
| 2019-12-31 | 0.00% |
| 2019-09-30 | 0.00% |
| 2019-06-30 | -73.11% |
| 2019-03-31 | 0.00% |
| 2018-12-31 | -1704.03% |
| 2018-09-30 | -5699.06% |
| 2018-06-30 | -601.12% |
| 2018-03-31 | -2970.74% |
| 2017-12-31 | 452.07% |
| 2017-09-30 | -1056.46% |
| 2017-06-30 | -418.32% |
| 2017-03-31 | -600.10% |
